esketamine spravato - Search News

Ketamine Nasal Spray Approved

Monthly Prescribing Reference · 2d

Spravato Approved as Monotherapy for Treatment-Resistant Depression

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants.

Times Now on MSN · 4d

What is Spravato, an FDA-approved First Standalone Esketamine-based Nasal Spray Monotherapy for Depression?

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and manufactured by Johnson & Johnson, this ketamine-based drug has been approved as a standalone treatment for major depressive disorder or MDD.

Boing Boing on MSN2d

FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results